Zydus

Pharmaceutical major Zydus has launched a new biosimilar for cancer treatment, reinforcing its commitment to improving access to advanced therapies at more affordable prices. The launch comes amid rising demand for cost-effective oncology solutions as cancer incidence continues to grow and treatment expenses escalate. By adding another biosimilar to its portfolio, Zydus aims to address both clinical needs and economic pressures faced by patients and healthcare systems.

Zydus Lifesciences and RK Pharma have entered into a licensing agreement aimed at enhancing the distribution and commercialization of key pharmaceutical products. The deal enables RK Pharma to leverage Zydus’ proprietary formulations and manufacturing expertise, while Zydus gains broader market access and optimized product penetration. The partnership reflects a strategic approach to strengthening presence in domestic and regional markets, particularly in segments showing high growth potential.

Zydus Lifesciences has unveiled a new cough-relief formulation packaged in spouted pouches, marking a strategic shift toward more consumer-friendly and travel-ready medication formats. The launch aims to address a growing demand for convenient, single-use therapeutic solutions, particularly among younger consumers and frequent travelers. By adopting an unconventional packaging style more commonly seen in food and wellness products, Zydus seeks to differentiate its offerings in India’s highly competitive over-the-counter (OTC) market.